Entrada Therapeutics, Inc.
TRDA
$6.36
$0.101.60%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 875.00K | 1.30M | 1.61M | 1.95M | 20.56M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 875.00K | 1.30M | 1.61M | 1.95M | 20.56M |
| Cost of Revenue | 33.05M | 32.26M | 38.36M | 37.88M | 32.07M |
| Gross Profit | -32.18M | -30.96M | -36.75M | -35.93M | -11.52M |
| SG&A Expenses | 10.12M | 9.35M | 10.30M | 10.92M | 10.27M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.18M | 41.61M | 48.67M | 48.80M | 42.35M |
| Operating Income | -42.30M | -40.31M | -47.05M | -46.85M | -21.79M |
| Income Before Tax | -39.68M | -39.07M | -43.48M | -42.93M | -17.35M |
| Income Tax Expenses | 38.00K | 92.00K | 654.00K | 178.00K | -- |
| Earnings from Continuing Operations | -39.72M | -39.16M | -44.13M | -43.10M | -17.35M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -39.72M | -39.16M | -44.13M | -43.10M | -17.35M |
| EBIT | -42.30M | -40.31M | -47.05M | -46.85M | -21.79M |
| EBITDA | -41.50M | -39.42M | -45.82M | -45.82M | -20.84M |
| EPS Basic | -0.95 | -0.94 | -1.06 | -1.04 | -0.42 |
| Normalized Basic EPS | -0.59 | -0.56 | -0.66 | -0.65 | -0.26 |
| EPS Diluted | -0.95 | -0.94 | -1.06 | -1.04 | -0.42 |
| Normalized Diluted EPS | -0.59 | -0.56 | -0.66 | -0.65 | -0.26 |
| Average Basic Shares Outstanding | 41.84M | 41.60M | 41.46M | 41.34M | 41.07M |
| Average Diluted Shares Outstanding | 41.84M | 41.60M | 41.46M | 41.34M | 41.07M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |